Fulcrum Therapeutics (FULC) announced that it has commenced an underwritten public offering of $150M of shares of its common stock. All of the shares in the proposed offering are to be sold by Fulcrum. J.P. Morgan, Leerink Partners, and Cantor are acting as book-running managers for the proposed offering. Oppenheimer & Co. and Truist Securities are also acting as book-running managers for the proposed offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FULC:
- Fulcrum Therapeutics price target raised to $25 from $20 at Stifel
- Fulcrum Therapeutics price target raised to $24 from $15 at Cantor Fitzgerald
- Fulcrum Therapeutics price target raised to $10 from $7 at RBC Capital
- Fulcrum Therapeutics Reports Positive Phase 1b Trial Results
- Fulcrum Therapeutics price target raised to $23 from $16 at Piper Sandler